Company Introduction

Guzip Biomarkers Corporation, a medical startup of Taiwan and a spinoff of Taipei Medical University (TMU) in 2018, is set to revolutionize the diagnostic strategy for women’s health and quality of life.
酷氏基因是2018年自台北醫學大學衍生的新創公司，致力於子宮內膜癌的檢驗試劑開發。
 
本公司專注於表觀遺傳學（Epigenetics）的研究，不斷在DNA甲基化研究領域中尋求更多應用的可能性，第一項產品是開發子宮內膜癌檢驗試劑，以期提供健康管理單位作為個人化醫療服務之依據，為造福女性健康作出貢獻。
 
公司願景：致力成為婦女健康照護產業的佼佼者，為婦女提供安全、經濟、有效的檢測產品。
 
公司使命：追求品質、不斷創新。
 
公司產品：安蓓®基因檢測試劑 (MPap®)。

Brief description of main products or services 

Our technology and service are centralized on “DNA Methylation Biomarkers” for early and precise cancer diagnosis and women’s wellbeing. Guzip Biomarkers Corporation is a medical startup of Taiwan established in 2018, and the MPap® Assay using the least invasive cervical scraping is our first product as a Laboratory Developed Test (LDT) service and In Vitro Diagnostics (IVD) medical device for risk of Endometrial Cancer (EC). The DNA methylation detection of the BHLHE22 and CDO1 genes, combined with the secondary risk factors of age and body mass index (BMI), is developed as an auxiliary EC diagnosis, and the test result provides a reference for physician to proceed an invasive endometrial biopsy or other alternatives.